New Directions in the Biology and Therapy of Chronic Myeloid Leukemia

Albert Deisseroth(National Cancer Institute), Marian Chou(The University of Texas MD Anderson Cancer Center), L. Huston(The University of Texas MD Anderson Cancer Center), Moshe Talpaz(University of Michigan), Steven M. Kornblau(The University of Texas MD Anderson Cancer Center), Ying Cha(The University of Texas MD Anderson Cancer Center), A Wedrychowski(The University of Texas MD Anderson Cancer Center), Debra Ellerson(The University of Texas MD Anderson Cancer Center), Laurent Gressot(The University of Texas MD Anderson Cancer Center), Hanchun Chen(Shanghai Jiao Tong University), Elizabeth Johnson(The University of Texas MD Anderson Cancer Center), Issa F. Khouri(The University of Texas MD Anderson Cancer Center), David Seong(Stanford Medicine), Eugenia Gaozza(The University of Texas MD Anderson Cancer Center), Guiying Hu(The University of Texas MD Anderson Cancer Center), Marylynńe Filaccio(The University of Texas MD Anderson Cancer Center), O. M. Zack Howard(Center for Cancer Research), Simon H. Sims(Sigma Genosys (United States)), Tianying Yuan(Tsinghua–Berkeley Shenzhen Institute), Auro del Giglio(Faculdade de Medicina do ABC), Michael Andreeff(The University of Texas MD Anderson Cancer Center), Soon‐Pal Suh(The University of Texas MD Anderson Cancer Center), Wei Zhang(The University of Texas MD Anderson Cancer Center), Hagop Kantarjian(The University of Texas MD Anderson Cancer Center), R. Champlin(The University of Texas MD Anderson Cancer Center), Pei Gao(The University of Texas MD Anderson Cancer Center), B Andersson(The University of Texas MD Anderson Cancer Center), David F. Claxton(The University of Texas MD Anderson Cancer Center)
Leukemia & lymphoma/Leukemia and lymphoma
January 1, 1992
10.3109/10428199209064884
Cited by 6

Related Papers

Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
|New England Journal of Medicine|2002|2k
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
|Nature Genetics|2013|1.2k
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
|Blood|1997|1.2k
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
|Journal of Clinical Oncology|1998|927